Efficacy of edaravone on coronary artery bypass patients with myocardial damage after ischemia and reperfusion: a meta analysis.
OBJECTIVE
To assess the efficacy and safety of edaravone for myocardial damage during myocardial ischemia and reperfusion (I/R).


METHODS
We included randomized controlled trials that compared edaravone with placebo or no intervention in patients with acute myocardial infarction or undergoing coronary artery bypass. Two authors selected eligible trials, assessed trial quality and independently extracted the data.


RESULTS
Seven clinical trials were eventually included and analyzed in this study, involving 148 participants. Four trials were defined as waiting assessment. All of the three remaining trials compared edaravone and another treatment combined with other treatment alone, used the same dose of edaravone injections (60 mg per day) and course of treatment (14 days), evaluated the effect of edaravone at different times, applied different methods, reported adverse events, and showed no differences between the treatment group and the control group. When pooling all of the trials in one dataset, edaravone appeared to decrease the proportion of participant with marked myocardial damage during I/R as compared with the control group. The meta-analysis also revealed decreased CK-MB, cTnI and MDA, and increased content of SOD.


CONCLUSIONS
Due to the moderate risk of bias and small sample, our observation of an effective treatment trend of edaravone for I/R requires future larger, high-quality trials to confirm.
First Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital Beijing 100853, China ; No. 2 Clinic, Management Support Bureau, Chinese PLA General Logistics Department Beijing 100071, China.
Chenhong
C
Zheng
Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support Bureau Beijing 100071, China.
Shouying
S
Liu
Cancer Center, Chinese PLA General Hospital & Chinese PLA Medical School No. 28 Fuxing Road, Haidian District, Beijing 100853, China.
Peiliang
P
Geng
No. 2 Clinic, Management Support Bureau, Chinese PLA General Logistics Department Beijing 100071, China.
Huiming
H
Zhang
First Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital Beijing 100853, China.
Hongpeng
H
Zhang
First Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital Beijing 100853, China.
Airong
A
Tang
First Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital Beijing 100853, China.
Xiaohua
X
Xie
Myocardial; edaraone; ischemia; reperfusion